Compare Ascendis Pharma A/S (ASND) vs Byrna Technologies Inc (BYRN) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

BYRN trades at $3.865, down 1.9% today, with a bearish technical signal from moving averages and oscillators. Recent Q2 2026 results showed a significant revenue decline of 42.5% year-over-year and a net loss of $0.44 per share, missing estimates. The company faces challenges in sales and marketing effectiveness but is undertaking strategic initiatives including a recent acquisition and marketing overhaul to revive growth.

The outlook remains cautious due to persistent profitability issues and negative cash flow trends. While analyst consensus is predominantly Buy (71%), reflecting long-term potential in the less-lethal defense market, near-term risks from execution missteps and competitive pressures warrant careful monitoring. Investor sentiment is mixed amid ongoing operational reset efforts.